Journey Medical Co. (NASDAQ: DERM) was given a new $10.50 price target on by analysts at Industrial Alliance Securities.
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Journey Medical Co. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea